Lipids — MOH Clinical Practice Guidelines 2/2016

Objectives

Provide evidence-based, clinically practical guidance for physicians and other healthcare professionals, particularly in primary care, to prevent and manage dyslipidaemia and reduce coronary artery disease risk in Singapore while preserving individual clinical judgement.[1][2]The guideline addresses lipid measurement, dyslipidaemia classification, cardiovascular risk assessment, lifestyle management, pharmacotherapy, special populations and quality indicators.[1]

• Stratify individuals as very high, high, intermediate or low cardiovascular risk, using established cardiovascular disease, diabetes, chronic kidney disease, familial hypercholesterolaemia and a calculated 10-year coronary artery disease risk where applicable.[3][4]
• Apply risk-based low-density lipoprotein cholesterol targets, generally below 2.0 or 2.1 mmol/L for very high risk, below 2.6 mmol/L for high risk, below 3.4 mmol/L for intermediate risk and below 4.1 mmol/L for low risk, while considering more intensive treatment when benefits outweigh risks.[5][6][7]
• Identify lipid disorders through routine screening for men and women aged 40 years and older, and consider screening adults aged 18 years and older who have diabetes, multiple coronary artery disease risk factors or relevant family history.[5][8]
• Promote smoking cessation, healthy weight reduction where indicated, regular aerobic activity, prudent alcohol consumption and dietary patterns rich in wholegrains, vegetables, fruit, legumes, nuts, fish and unsaturated oils.[9][10]
• Use statins as first-line treatment for hypercholesterolaemia and mixed dyslipidaemia, while prioritising triglyceride reduction with fibrates for triglycerides above 4.5 mmol/L to reduce acute pancreatitis risk.[11][12]
• Tailor management for children, pregnancy, older age, chronic kidney or liver disease, and familial hypercholesterolaemia, including screening first-degree relatives of people diagnosed with familial hypercholesterolaemia.[13][14][15]

Implementation

Deliver the guidance through a simplified clinical practice guideline that applies available evidence to individual patient data, recognises that medical knowledge and standards of care evolve, and supports rather than replaces professional judgement.[16][1]Development used a multidisciplinary model involving Ministry of Health-appointed cardiologists, endocrinologists, lipid specialists, public health specialists and family physicians, with professional-body review and endorsement.[2][17]

• Obtain fasting lipid profiles including total cholesterol, triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol after 10 to 12 hours of fasting; use the Friedewald formula where triglycerides are no higher than 4.5 mmol/L and direct low-density lipoprotein cholesterol measurement where available above this threshold.[18]
• Assess secondary causes of dyslipidaemia, including diabetes mellitus, chronic kidney disease, hypothyroidism, alcohol misuse, cholestasis, pregnancy and relevant medicines, before selecting treatment.[19]
• Repeat lipid screening every three years for people with low risk and lipids within target, and annually for people at high or very high coronary artery disease risk; defer testing after febrile illness where appropriate and reassess three months after myocardial infarction.[5][8]
• Deliver lifestyle counselling through practical advice on 150 to 300 minutes of moderate-intensity aerobic activity weekly, dietary substitution of healthier grains, proteins, dairy products and oils, reduced saturated and trans fats, and restricted sugars for people with raised triglycerides.[20][10]
• Escalate pharmacotherapy from the maximum tolerated statin dose to ezetimibe or, where appropriate, resins and selected combination regimens; use fenofibrate rather than gemfibrozil when combining a fibrate with a statin.[21][22][23]
• Refer patients to lipid specialists when low-density lipoprotein cholesterol remains above target or triglycerides remain above 4.5 mmol/L despite dietary measures and maximum tolerated drug therapy.[22][13]
• Monitor treatment safety by checking glycaemic control in people at risk of diabetes after statin initiation, investigating muscle symptoms with creatine kinase testing, and assessing liver enzymes when hepatotoxicity is suspected.[24][25]
• Stop or adjust statin treatment when serum transaminases exceed three times the upper limit of normal or when substantial creatine kinase elevation occurs with muscle pain; consider reintroduction at a lower dose after liver function normalises.[24][25]
• Measure attainment of recommended low-density lipoprotein cholesterol targets as a quality indicator, while recognising that clinical judgement is needed and universal target attainment is not appropriate; review stable treated patients' lipid levels at least annually.[26][27]
• Support professional uptake through online Continuing Medical Education and self-assessment mechanisms hosted through the Singapore Medical Council Online Continuing Medical Education system and Singapore Medical Journal channels.[28]

The guideline is scheduled for review five years after publication, or sooner if important new evidence requires substantive revision, coordinated with revision of the Ministry of Health cardiovascular disease screening guideline.[29]The available material does not specify a dedicated implementation budget, financing mechanism, programme-level reporting system, surveillance framework or named body accountable for routine delivery performance.[30][29][8]

Monitoring & Evaluation

The guideline combines clinical monitoring, treatment-safety surveillance, risk reassessment and lipid-management quality indicators. It supports periodic review of the guideline itself, but the available content does not establish a comprehensive programme-level reporting, surveillance or accountability system.[29][26][27]

• Use lipid measurement to support screening and follow-up, with testing every three years for people with low triglycerides and low-density lipoprotein cholesterol within target, and annually for people at high or very high coronary artery disease risk.[5][8]
• Repeat lipid measurement three months after myocardial infarction because cholesterol concentrations may be temporarily depressed after the event.[5][8][18]
• Defer lipid testing for at least two weeks after febrile illness when clinically appropriate, as acute illness can affect results.[5][8]
• Measure attainment of risk-based low-density lipoprotein cholesterol targets as a quality indicator, while excluding people aged over 75 years from target-attainment measurement and recognising that 100% attainment is not appropriate.[26][27]
• Review lipid levels at least every 12 months for patients on stable lipid-modifying treatment who have achieved target levels, and for untreated very high- or high-risk patients who have achieved targets.[27]
• Use low-density lipoprotein cholesterol targets and persistent triglyceride concentrations above 4.5 mmol/L, despite lifestyle measures and maximum tolerated drug therapy, as triggers for specialist referral.[23][13]
• Consider reducing statin dose where two consecutive low-density lipoprotein cholesterol results are below approximately 1.0 mmol/L.[20][31]
• Monitor glycaemic control more closely after initiating statins in people with pre-diabetes, impaired fasting glucose or impaired glucose tolerance.[24][31]
• Establish baseline creatine kinase and liver transaminase measurements before statin treatment, but avoid routine repeat testing in well, asymptomatic patients.[25]
• Measure creatine kinase when statin-treated patients develop muscle symptoms, and measure alanine aminotransferase and aspartate aminotransferase when symptoms suggest hepatotoxicity.[24][25]
• Stop statins where serum transaminases exceed three times the upper limit of normal, with possible lower-dose reintroduction after liver function normalises.[24][25]
• Stop statins where creatine kinase exceeds five to ten times the upper limit of normal with muscle pain, and consider dose reduction or discontinuation for troublesome muscle symptoms even without raised creatine kinase.[24][25]
• Monitor children receiving statins through creatine kinase and transaminase testing before treatment, after regimen changes and every four months thereafter.[32][13]
• Monitor creatine kinase and renal function during statin therapy for chronic kidney disease, and monitor transaminases, creatine kinase and fibrate-related adverse effects in chronic liver disease where indicated.[14][15]
• Use 10-year coronary artery disease risk tables for Chinese, Malay and Indian men and women in Singapore, based on Framingham-derived functions recalibrated with local epidemiological data.[3][4]
• Grade recommendations by strength and evidence level, including Grade A to Grade D classifications, and base specified target and triglyceride recommendations on randomised controlled trial evidence.[5][20][11][6][7]
• Review the guideline five years after publication, or earlier where new evidence requires substantive revision, coordinating this with revision of the Ministry of Health guideline on cardiovascular disease and risk-factor screening.[29]
• Use process indicators and their measurement frequency as set out in Table 14, although the available extract does not provide the individual indicators or frequencies.[30][2]

The available material does not specify a routine reporting process, audit cycle, surveillance system, evaluation timetable, named accountable body or enforcement mechanism beyond clinical quality measures, guideline review and the multidisciplinary guideline-development workgroup.[30][2][33][4][26][27]

Costing & Financing

Cost considerations are acknowledged in decisions on medicine choice and treatment intensification, but the guideline excerpts do not provide a budget, financing mechanism, funding source, resource-mobilisation plan, funding gap or quantified economic assumption.[6][7][14][34]

• Consider medication cost alongside expected benefit and potential adverse effects when increasing statin intensity or selecting higher-dose treatment.[6][31]
• Use generic formulations where they meet prescribed standards, as they cost less than non-generic medicines.[22][23][13]
• Recognise statins and fibrates as cost-effective options for primary and secondary prevention, with generic availability described as improving their cost-effectiveness.[23]
• Balance uncertain cardiovascular benefit against treatment cost and adverse effects when deciding whether to initiate or continue statins for people on dialysis.[14]
• Note that bibliographic material includes economic evaluations, cost-effectiveness studies and potential savings from lipid-lowering treatment, but it supplies no guideline-specific financial estimates or economic model.[35][34]

No explicit allocation, price, total programme cost, currency-denominated expenditure, financing source or time-bound funding commitment is provided in the supplied text.[16][1][5][20][11]